Zydus Lifesciences LimitedNSE: ZYDUSLIFE

Press Release Jul 17 2024

· Issued by Zydus Lifesciences Limited

Filed with NSE · · 3 pages · English

Summary by 6ix AI

Zydus Lifesciences Limited has announced a non-exclusive patent licensing agreement with Takeda for the drug Vonoprazan in India. This agreement allows Zydus to market Vonoprazan, branded as Vault, which is a treatment for gastro duodenal ulcers and GERD. The launch of Vault will provide a new treatment option for managing GERD and other acid peptic disorders in India. Dr. Sharvil Patel, Managing Director, emphasized the company's commitment to offering innovative healthcare solutions.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Release

Zydus Lifesciences Limited has informed the Exchange regarding a press release dated July 17, 2024, titled "Zydus announces non-exclusive patent licensing agreement with Takeda for Vault? (Vonoprazan) in India".

Zydus Lifesciences Limited on 6ix

Earlier from Zydus Lifesciences

Later from Zydus Lifesciences

All Zydus Lifesciences news releases